NDLI: Evidence of SARS-CoV-2 convergent evolution in immunosuppressed patients treated with antiviral therapies

Content Provider	Springer Nature : BioMed Central
Author	Feng, Shuchen Reid, Gail E. Clark, Nina M. Harrington, Amanda Uprichard, Susan L. Baker, Susan C.
Abstract	Background The factors contributing to the accelerated convergent evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are not fully understood. Unraveling the contribution of viral replication in immunocompromised patients is important for the early detection of novel mutations and developing approaches to limit COVID-19. Methods We deep sequenced SARS-CoV-2 RNA from 192 patients (64% hospitalized, 39% immunosuppressed) and compared the viral genetic diversity within the patient groups of different immunity and hospitalization status. Serial sampling of 14 patients was evaluated for viral evolution in response to antiviral treatments. Results We identified hospitalized and immunosuppressed patients with significantly higher levels of viral genetic diversity and variability. Further evaluation of serial samples revealed accumulated mutations associated with escape from neutralizing antibodies in a subset of the immunosuppressed patients treated with antiviral therapies. Interestingly, the accumulated viral mutations that arose in this early Omicron wave, which were not common in the patient viral lineages, represent convergent mutations that are prevalent in the later Omicron sublineages, including the XBB, BA.2.86.1 and its descendent JN sublineages. Conclusions Our results illustrate the importance of identifying convergent mutations generated during antiviral therapy in immunosuppressed patients, as they may contribute to the future evolutionary landscape of SARS-CoV-2. Our study also provides evidence of a correlation between SARS-CoV-2 convergent mutations and specific antiviral treatments. Evaluating high-confidence genomes from distinct waves in the pandemic with detailed patient metadata allows for discerning of convergent mutations that contribute to the ongoing evolution of SARS-CoV-2.
Related Links	https://virologyj.biomedcentral.com/counter/pdf/10.1186/s12985-024-02378-y.pdf
Ending Page	13
Page Count	13
Starting Page	1
File Format	HTM / HTML
DOI	10.1186/s12985-024-02378-y
Journal	Virology Journal
Issue Number	1
Volume Number	21
Language	English
Publisher	BioMed Central
Publisher Date	2024-05-07
Access Restriction	Open
Subject Keyword	Virology SARS-CoV-2 evolution Convergent evolution COVID-19 Immunosuppressed patients iSNVs Monoclonal antibody treatment Antiviral treatment
Content Type	Text
Resource Type	Article
Subject	Virology Infectious Diseases
Journal Impact Factor	4/2023
5-Year Journal Impact Factor	3.8/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Recommendations for Anti-SARS-CoV-2 Monoclonal Antibody Treatment of Patients with COVID-19.

Impact of Early SARS-CoV-2 Antiviral Therapy on Disease Progression.

Safety and efficacy of molnupiravir in SARS-CoV-2-infected patients: A real-life experience.

Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients.

Cartography of SARS-CoV-2 variants based on the susceptibility to therapeutic monoclonal antibodies.

Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study

Development of neutralizing antibody responses against SARS-CoV-2 in COVID-19 patients.

Clinical application of SARS-CoV-2 antibody detection and monoclonal antibody therapies against COVID-19.

Evaluation of 2 commercial anti-SARS-CoV-2 antibody assays in an immunocompetent and immunocompromised inpatient population with COVID-19.

Evidence of SARS-CoV-2 convergent evolution in immunosuppressed patients treated with antiviral therapies

Similar Documents

Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Recommendations for Anti-SARS-CoV-2 Monoclonal Antibody Treatment of Patients with COVID-19.

Impact of Early SARS-CoV-2 Antiviral Therapy on Disease Progression.

Safety and efficacy of molnupiravir in SARS-CoV-2-infected patients: A real-life experience.

Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients.

Cartography of SARS-CoV-2 variants based on the susceptibility to therapeutic monoclonal antibodies.

Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study

Development of neutralizing antibody responses against SARS-CoV-2 in COVID-19 patients.

Clinical application of SARS-CoV-2 antibody detection and monoclonal antibody therapies against COVID-19.

Evaluation of 2 commercial anti-SARS-CoV-2 antibody assays in an immunocompetent and immunocompromised inpatient population with COVID-19.

Evidence of SARS-CoV-2 convergent evolution in immunosuppressed patients treated with antiviral therapies